The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $115.39

Today's change+1.27 +1.11%
Updated June 22 10:23 AM EDT. Delayed by at least 15 minutes.
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $115.39

Today's change+1.27 +1.11%
Updated June 22 10:23 AM EDT. Delayed by at least 15 minutes.

Taro Pharmaceutical Industries Ltd Hits New 20-day High

Taro Pharmaceutical Industries Ltd is up today by (U.S.)$1.27 or 1.11% to (U.S.)$115.39 and setting a new 20-day high. Over the last five days, shares have gained 6.19% and 9.61% year to date. Shares have underperformed the S&P 500 by 35.34% during the last year.

Key company metrics

  • Open(U.S.) $114.37
  • Previous close(U.S.) $114.12
  • High(U.S.) $115.39
  • Low(U.S.) $112.74
  • Bid / Ask(U.S.) $114.65 / (U.S.) $115.50
  • YTD % change+9.61%
  • Volume6,761
  • Average volume (10-day)61,630
  • Average volume (1-month)76,647
  • Average volume (3-month)80,878
  • 52-week range(U.S.) $92.28 to (U.S.) $148.00
  • Beta0.65
  • Trailing P/E10.44×
  • P/E 1 year forward12.02×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $11.05
Updated June 22 10:23 AM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+51.97%

Based on its net profit margin of 51.97%, Taro Pharmaceutical Industries Ltd is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.31%Sector:HealthcareIndustry:Pharmaceuticals - Diversified

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue220229234265
Total other revenue--------
Total revenue220229234265
Gross profit167177183224
Total cost of revenue53515141
Total operating expense91879183
Selling / general / administrative20212223
Research & development18151820
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0000
Other operating expenses, total--------
Operating income129142143182
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax161160140138
Income after tax140124110115
Income tax, total20363023
Net income140124110115
Total adjustments to net income--------
Net income before extra. items140124110115
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items140124110115
Inc. avail. to common incl. extra. items140124110115
Diluted net income140124110115
Dilution adjustment--------
Diluted weighted average shares41414243
Diluted EPS excluding extraordinary itemsvalue per share3.423.002.602.68
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share3.423.002.602.69